



Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

February 8, 2023

IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the upcoming SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET.

To register in advance for the presentation webcast, sign up [here](#).

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company's website at <https://ir.eledon.com/events-and-presentations/events>.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: [LinkedIn](#); [Twitter](#)

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

Source: Eledon Pharmaceuticals



Source: Eledon Pharmaceuticals, Inc.